News
1d
TipRanks on MSNRegeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Prurigo Nodularis Treatment
The ongoing study could significantly impact the stock performance of Regeneron and Sanofi, as successful results may enhance their market position and investor confidence. The development of ...
Nektar Therapeutics is fairly valued based on rNPV modeling, but multiple near-term catalysts could drive upside. Learn why ...
In a study known as CROWNS-2 published in JAMA, the researchers randomly assigned 180 adults with CRSwNP to stapokibart (300 ...
Anabelle Terry, a slender, self-possessed 13-year-old, has heard the peanut butter story her entire life. A visit to an ...
6d
MedPage Today on MSNNovel Biologic Tackles Severe Chronic Rhinosinusitis With Nasal Polyps
For severe chronic rhinosinusitis with nasal polyps, novel stapokibart reduced symptoms and polyp size atop treatment with a ...
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.
Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage study, but that was less than previous trial results for Novo Nordisk's ...
Minghui Pharmaceutical has secured $131 million in what the company describes as a “pre-IPO” round to fuel the potential launch of its dermatitis cream in China as well as various clinical ...
Pill Causes Major Weight Loss in Eli Lilly Trial’s Results The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the year.
In Westchester County, Regeneron, a top bio-tech company, has workers focused on mRNA research projects, including one aimed at "unlocking the next generation of cancer fighting treatments ...
A new trial date is set for the man charged with murder in the death of a woman whose body was found in a Sissonville well in May 2021.A pre-trial hearing for M ...
Terns Pharmaceuticals is planning to stop inve | Terns Pharmaceuticals is planning to stop investing in metabolic disease clinical development at the end of 2025, starting a countdown to potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results